GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (FRA:ATQP) » Definitions » Cyclically Adjusted PS Ratio

Vericel (FRA:ATQP) Cyclically Adjusted PS Ratio : 11.37 (As of Jun. 03, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Vericel Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Vericel's current share price is €35.60. Vericel's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €3.13. Vericel's Cyclically Adjusted PS Ratio for today is 11.37.

The historical rank and industry rank for Vericel's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:ATQP' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.93   Med: 10.25   Max: 31.79
Current: 11.82

During the past years, Vericel's highest Cyclically Adjusted PS Ratio was 31.79. The lowest was 1.93. And the median was 10.25.

FRA:ATQP's Cyclically Adjusted PS Ratio is ranked worse than
72.38% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs FRA:ATQP: 11.82

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vericel's adjusted revenue per share data for the three months ended in Mar. 2025 was €0.975. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €3.13 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vericel Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vericel's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Cyclically Adjusted PS Ratio Chart

Vericel Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.46 16.38 9.45 11.01 16.13

Vericel Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.69 13.68 12.57 16.13 12.77

Competitive Comparison of Vericel's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vericel's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vericel's Cyclically Adjusted PS Ratio falls into.


;
;

Vericel Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vericel's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=35.60/3.13
=11.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vericel's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vericel's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.975/134.9266*134.9266
=0.975

Current CPI (Mar. 2025) = 134.9266.

Vericel Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.509 100.684 0.682
201509 0.424 100.392 0.570
201512 0.598 99.792 0.809
201603 0.560 100.470 0.752
201606 0.503 101.688 0.667
201609 0.428 101.861 0.567
201612 0.644 101.863 0.853
201703 0.274 102.862 0.359
201706 0.460 103.349 0.601
201709 0.355 104.136 0.460
201712 0.563 104.011 0.730
201803 0.405 105.290 0.519
201806 0.424 106.317 0.538
201809 0.449 106.507 0.569
201812 0.633 105.998 0.806
201903 0.441 107.251 0.555
201906 0.527 108.070 0.658
201909 0.593 108.329 0.739
201912 0.792 108.420 0.986
202003 0.537 108.902 0.665
202006 0.394 108.767 0.489
202009 0.579 109.815 0.711
202012 0.691 109.897 0.848
202103 0.631 111.754 0.762
202106 0.707 114.631 0.832
202109 0.628 115.734 0.732
202112 0.900 117.630 1.032
202203 0.697 121.301 0.775
202206 0.744 125.017 0.803
202209 0.825 125.227 0.889
202212 1.053 125.222 1.135
202303 0.808 127.348 0.856
202306 0.891 128.729 0.934
202309 0.896 129.860 0.931
202312 1.248 129.419 1.301
202403 0.980 131.776 1.003
202406 1.005 132.554 1.023
202409 1.063 133.029 1.078
202412 1.184 133.157 1.200
202503 0.975 134.927 0.975

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vericel  (FRA:ATQP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vericel Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vericel's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel Business Description

Industry
Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Headlines

No Headlines